A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01307267
• Other study ID #: B1641001
• Secondary ID: 2011-002799-17
• Status: Completed
• Phase: Phase 1
• Start date: June 21, 2011
• Est. completion date: February 20, 2019

Study information

• Verified date: March 2020
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 190
• Est. completion date: February 20, 2019
• Est. primary completion date: February 20, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Portion A: Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy or B cell lymphoma, for which no curative therapy is available. Portion A expansion includes patients who have documented disease progression on a checkpoint inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose expansion stage are required to provide archival or baseline (obtained during the screening period) tumor biopsies.

• Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which no curative therapy is available. Patients enrolled in the expansion cohort must have archival tissue available, sampled within 6 months of study entry. The Expansion cohort includes patients with FL or DLBCL with relapsed or refractory disease.

• Measurable disease with at least one extranodal tumor mass >1.0 cm in the greatest transverse diameter (GTD) or in the case of malignant lymph nodes >1.5 cm in the GTD.

• ECOG performance status of = 1.

• Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) = 1.5 x 109/L, platelet count =100 x 109/L, hemoglobin >9.0 g/dL. For Portion B: ANC = 1.0 x 109/L, platelet count = 75 x 109/L, and hemoglobin = 8.0 g/dL. In both cases, patients must be transfusion independent at least 14 days prior to screening.

• Serum creatinine = 2 x ULN or estimated creatinine clearance = 50 ml/min.

• Total serum bilirubin = 1.5 x ULN unless the patient has documented Gilbert syndrome and AST and ALT = 2.5 x ULN.

Exclusion Criteria

• Patients with known symptomatic brain metastases requiring steroids.

• Prior allogeneic hematopoietic stem cell transplant.

• Immunosuppressive regimens involving systemic corticosteroids within 14 days before the first dose of study treatment.

• Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation therapy within 14 days of the first dose of study drug.

• Autoimmune disorders and other diseases that compromise or impair the immune system.

• Unstable or serious concurrent medical conditions in the previous 6 months.

• Prior therapy with any anti CD137 monoclonal antibody.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Renal Cell
• Carcinoma, Squamous Cell
• Carcinoma, Squamous Cell of Head and Neck
• Lymphoma
• Lymphoma, Follicular
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Non-Hodgkin
• Malignant Melanoma
• Melanoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• PF-05082566
Intravenous, Dose escalation, once per month
• rituximab
Intravenous, 375 mg/m2, once per week for 4 weeks
• PF-05082566
IV, Dose escalation, once per month

Locations

Country	Name	City	State
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
France	Centre d'investigation clinique	RENNES cedex 9
Italy	Az. Ospedaliera-Univer. di Bologna Policlinico S. Orsola Malpighi	Bologna	BO
Italy	Ospedale San Raffaele di Milano	Milano	MI
Japan	Akita University Hospital	Akita
Japan	National Cancer Center Hospital East	Kashiwa	Chiba
Japan	The Cancer Institute Hospital of Japanese Foundation for Cancer Research	Tokyo
United States	University of Michigan Health System	Ann Arbor	Michigan
United States	Emory University Hospital	Atlanta	Georgia
United States	Emory University Hospital Midtown	Atlanta	Georgia
United States	The Emory Clinic	Atlanta	Georgia
United States	The Emory Clinic, Building A	Atlanta	Georgia
United States	Winship Cancer Institute	Atlanta	Georgia
United States	Brigham and Woman's Hospital	Boston	Massachusetts
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Siteman Cancer Center-West County	Creve Coeur	Missouri
United States	City of Hope	Duarte	California
United States	The University of Texas - M.D. Anderson Cancer Center	Houston	Texas
United States	UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital)	La Jolla	California
United States	UC San Diego Moores Cancer Center	La Jolla	California
United States	UC San Diego Moores Cancer Center-Investigational Drug Services	La Jolla	California
United States	Research Administration Office: Clinical Research Unit	Los Angeles	California
United States	Ronald Reagan UCLA Medical Center, Drug Information Center	Los Angeles	California
United States	UCLA Bowyer Clinic	Los Angeles	California
United States	UCLA Hematology-Oncology Clinic	Los Angeles	California
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Stanford University Medical Center	Palo Alto	California
United States	Stanford University Medical Center	Palo Alto	California
United States	Barnes-Jewish Hospital	Saint Louis	Missouri
United States	Barnes-Jewish Hospital	Saint Louis	Missouri
United States	Siteman Cancer Center- South County	Saint Louis	Missouri
United States	Washington University Infusion Center Pharmacy	Saint Louis	Missouri
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Siteman Cancer Center - St. Peters	Saint Peters	Missouri
United States	South Texas Accelerated Research Therapeutics, LLC	San Antonio	Texas
United States	UC San Diego Medical Center - Hillcrest	San Diego	California
United States	Santa Monica UCLA Hematology & Oncology Clinic	Santa Monica	California
United States	Seattle Cancer Care Alliance	Seattle	Washington
United States	University of Washington Medical Center	Seattle	Washington
United States	Stanford University Medical Center	Stanford	California
United States	Georgetown University Medical Center Department of Pharmacy, Research	Washington	District of Columbia
United States	MedStar Georgetown University Hospital	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia,  France,  Italy,  Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarkers Linked With Immunomodulation and Cytokine Release	This was an exploratory endpoint and no data were collected.	Days 1, 14, 29 and 57
Other	Exploratory Pharmacodynamic Biomarkers	This was an exploratory endpoint and no data were collected.	Days 1 and 21
Other	Patient-Reported Outcomes of PF-05082566 and Rituximab When Given in Combination in Follicular Lymphoma Participants	This was an exploratory endpoint and was not evaluated. Patient-reported outcome questionnaires were not completed as a result of administrative processing error.	Up to 2 years
Primary	Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A	DLT: Any of the following adverse events (AEs) occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 alone for Portion A and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (>)7 days; febrile neutropenia; neutropenic infection; Grade =3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade =3 hemolysis. Non-Hematologic: Grade =3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.	Cycle 1 Day 1 to Cycle 2 Day 29 in Portion A (up to 57 days, each cycle = 28 days)
Primary	Number of Participants With DLTs in First 2 Cycles of Portion B	DLT: Any of the following AEs occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 in combination with rituximab for Portion B and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (>)7 days; febrile neutropenia; neutropenic infection; Grade =3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade =3 hemolysis. Non-Hematologic: Grade =3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.	Cycle 1 Day 1 to Cycle 2 Day 29 in Portion B (up to 57 days, each cycle = 28 days)
Secondary	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) in Portion A	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.	Up to approximately 2 years
Secondary	Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade in Portion A	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).	Up to approximately 2 years
Secondary	Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A	Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.	Up to approximately 2 years
Secondary	Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A	Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.	Up to approximately 2 years
Secondary	Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion A	For vital signs in Portion A, blood pressure and pulse rate were measured. Clinical significance was determined by the investigator.	Up to approximately 2 years
Secondary	PF-05082566 Maximum Observed Serum Concentration (Cmax) in Portion A	Cmax of PF-05082566 was observed directly from data.	Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose
Secondary	PF-05082566 Pre-dose Trough Concentration During Multiple Dosing (Ctrough) in Portion A	Ctrough of PF-05082566 was observed directly from data.	Day 1 pre-dose of Cycle 2
Secondary	PF-05082566 Time for Maximum Observed Serum Concentration (Tmax) in Portion A	Tmax of PF-05082566 was observed directly from data as time of Cmax.	Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
Secondary	PF-05082566 Area Under the Serum Concentration-Time Profile (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUClast) in Portion A	AUClast of PF-05082566 was determined by linear/log trapezoidal method.	Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
Secondary	PF-05082566 AUC From Time 0 to Infinity (AUCinf) in Portion A	AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.	Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
Secondary	PF-05082566 AUC From Time 0 to Time of Dosing Interval (AUCtau) in Portion A	AUCtau of PF-05082566 was determined using linear/log trapezoidal method.	Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
Secondary	PF-05082566 Clearance (CL) in Portion A	CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2. It was reported in units of milliliter per hour per kilogram (mL/hr/kg).	Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
Secondary	PF-05082566 Volume of Distribution at Steady State (Vss) in Portion A	Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.	Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
Secondary	Number of Participants With Positive Anti-Drug Antibody (ADA) for PF-05082566 in Portion A	ADA for PF-05082566 was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer>=6.23.	Up to approximately 2 years
Secondary	Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion A	Categorical summarization criteria for QTc interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate): 1) absolute value of >450 to <=480 milliseconds (msec), >480 to <=500 msec, >500 msec; 2) a maximum change from baseline of >30 to <=60 msec or >60 msec.	Up to approximately 2 years
Secondary	Percentage of Participants Achieving Objective Response Per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 in Portion A	Objective response: confirmed best overall response (BOR) of complete response (CR) or partial response (PR) per RECIST version 1.1. BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-progression of disease (non-PD), indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: >=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and >=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Duration of Response in Portion A	Duration of response: the time from first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1) to the date of first documentation of objective progression of disease (PD) or death due to any cause. Objective PD per RECIST version 1.1: >=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeters (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions. This outcome measure reports the individual values for evaluable participants (instead of medians etc) due to the limited number of events.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Time to Response in Portion A	Time to response: the time from Cycle 1 Day 1 to the first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1). BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-PD, indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes decreased to normal size); PR: >=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and >=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Progression-Free Survival in Portion A	Progression-free survival: the time from Cycle 1 Day 1 to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Objective PD per RECIST version 1.1: >=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm; or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Overall Survival in Portion A	Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Number of Participants With Treatment-Emergent AEs and SAEs in Portion B	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.	Up to approximately 4 years
Secondary	Number of Participants With Treatment-Emergent AEs by Maximum NCI CTCAE Grade in Portion B	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).	Up to approximately 4 years
Secondary	Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B	Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.	Up to approximately 2 years
Secondary	Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B	Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.	Up to approximately 2 years
Secondary	Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion B	For vital signs in Portion B, blood pressure, pulse rate, and body temperature were measured. Clinical significance was determined by the investigator.	Up to approximately 2 years
Secondary	PF-05082566 Cmax in Portion B	Cmax of PF-05082566 was observed directly from data.	Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
Secondary	PF-05082566 Ctrough in Portion B	Ctrough of PF-05082566 was observed directly from data.	Day 1 pre-dose of Cycle 2
Secondary	PF-05082566 Tmax in Portion B	Tmax of PF-05082566 was observed directly from data as time of Cmax.	Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
Secondary	PF-05082566 AUClast in Portion B	AUClast of PF-05082566 was determined by linear/log trapezoidal method.	Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
Secondary	PF-05082566 AUCinf in Portion B	AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.	Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose.
Secondary	PF-05082566 AUCtau in Portion B	AUCtau of PF-05082566 was determined using linear/log trapezoidal method.	Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
Secondary	PF-05082566 CL in Portion B	CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2.	Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
Secondary	PF-05082566 Vss in Portion B	Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.	Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
Secondary	Rituximab Cmax and Ctrough in Portion B	Cmax and Ctrough of rituximab were observed directly from data.	Day 1 pre-dose of Cycle 2
Secondary	Number of Participants With Positive ADA for PF-05082566 and Rituximab in Portion B	ADA for PF-05082566 and rituximab was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer>=6.23. Positive ADA for rituximab: titer>=1.88.	Up to approximately 2 years
Secondary	Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion B	Categorical summarization criteria for QTc interval: 1) absolute value of >450 to <=480 milliseconds (msec), >480 to <=500 msec, >500 msec; 2) a maximum change from baseline of >30 to <=60 msec or >60 msec.	Up to approximately 2 years
Secondary	Percentage of Participants Achieving Objective Response Per Cheson 2007 Criteria in Portion B	Objective Response in Portion B was defined as BOR of CR or PR according to Cheson 2007 criteria. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or >=50% decrease in the sum of the product diameters [SPD] of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion >=15 mm in greatest transverse diameter [GTD], unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Duration of Response in Portion B	Duration of Response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from first documentation of objective response to the date of first documentation of objective PD or death due to any cause. Objective PD per Cheson 2007 was defined as: PD of index lesions (>=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion >=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Time to Response in Portion B	Time to response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from Cycle 1 Day 1 to the first documentation of objective response. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or >=50% decrease in the SPD of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion >=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Progression-Free Survival in Portion B	Progression-free survival in Portion B was defined as the time from Cycle 1 Day 1 to the date of the first documentation of objective PD (per Cheson 2007) or death due to any cause, whichever occurred first. Objective PD per Cheson 2007 was defined as: PD of index lesions (>=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion >=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
Secondary	Overall Survival in Portion B	Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.	Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)

External Links

•   To obtain contact information for a study center near you, click here.